echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Exclusive injections soared 600%, Chinese medicine particles broke into the top ten!

    Exclusive injections soared 600%, Chinese medicine particles broke into the top ten!

    • Last Update: 2021-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network February 4th, recently, Lizhu Group released 2020 earnings forecast, expected net profit of 1.6 billion to 1.8 billion yuan, up 25% to 40% YoY, exclusive products injected with eprasium sodium, hydrochloric acid pyridoline tablets, antiviral particles sales of rapid release of performance.
    brokerages expect the company to achieve net profit of more than 2 billion yuan and more than 2.3 billion yuan in 2021-2022.
    News that Lizhu's heavy biopharmaceutical injection recombinant human velvet is expected to be approved in 2021; Blasts are coming, ready to go! Multiple exclusive products skyrocketed, the market leader appears Table 1: Lizhu Fist exclusive products market situation Source: Mi Net Database Figure 1: Injection with Eprasin sodium health insurance Source: Minenet one-click retrieval injection with Eprasin sodium is Lizhu's exclusive product, 202 In the first half of 0, china's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal treatment and gastric acid secretion-related diseases of drug injection products TOP20 ranked seventh, up two places from 2019, growth rate of more than 600%.
    2019, sales of the exclusive product began to grow rapidly after it was negotiated into the National Health Care Directory, and the company expects significant growth in the future.
    , which is used to treat schizophrenia, is the first imitation of Lizhu and is currently the only domestic product to add varieties to the 2019 National Health Insurance Directory.
    the first half of 2020, the product successfully rushed into China's public medical institutions terminal psychostation drug in-service products TOP20 list, growth rate of 93.46 percent, while in China's urban physical pharmacy terminals are expected to grow by more than 400 percent in 2020.
    Lizhu has said that the company in 2019 for the field of neurological drugs has set up an independent line sales team, related products sales achieved rapid growth, the company's other variety of Malay acid fluorofosamine also has the potential for sustained rapid growth, in the first half of 2020 in China's public medical institutions terminal growth rate of more than 25%, and is expected to achieve positive growth in China's urban physical pharmacy terminal growth.
    Lizhu from 2019 to strengthen the offline promotion layout of OTC drugs, subsidiary Sichuan Everbright Pharmaceutical's exclusive products antiviral particles online brand dissemination efforts continue to increase, consumer-centr online communication interaction, chain drugstores have been well-promoted, in 2020 is expected to be in China's urban physical pharmacy terminals in the drug cold medicine in the ninth place, up three places, growth rate of nearly 60%.
    said it will continue to enhance its brand influence, deepen patient services, strengthen chain and online interactions, and promote clinical evidence building to enable the rapid development and growth of antiviral particles.
    Table 2: Market situation of non-exclusive products of Lizhu Fist Source: Minet database currently in the domestic market, liang propylene relin has Takeda's original research drugs, Lizhu's injection with acetic acid bright propylene reillin micro-ball and Beijing Boente Pharmaceuticals' injection of acetate bright propylene reillin slow release micro-ball.
    microball is a complex and difficult preparation technology, Lizhu in the integration of raw materials preparation has an absolute advantage, in China's public medical institutions terminal endocrine treatment drug injection brand, Lizhu from 2013 TOP5 to 2019 TOP2, 2020 market share rose again in the first half of 2010.
    The variety is currently in the endometrial-related diseases sales are more ideal, other adaptive disorders such as uterine fibroids, prostate cancer, pre menoque breast cancer, central precocious and so on there is better room for growth, Lizhu market share of the product is expected to continue to increase.
    Innovative biopharmaceus and high-end complex preparation transformation, the company gradually into the harvest period lizhu's exclusive Chinese medicine injection ginseng positive injection since the 2017 version of the National Health Insurance Directory limited scope of use, sales showed a downward trend year by year, the first half of 2020 in China's public medical institutions terminal Chinese medicine cancer disease drug injection products ranking has fallen out of the top five, less a performance growth of the fist products, Lizhu determined to seek transformation.
    Table 3: Lizhu declared micro-ball product situation Source: Mi-Net MED2.0 China Drug Review Database Micro-ball has high barriers to research and development and industrialization, can avoid the high risk of research and development of innovative drugs, but also avoid the fierce competition of generic drugs Data show that in the past three years, global sales of micro-ball preparations accounted for more than 50% of all sales of long-lasting slow-release preparations, the market potential can not be underestimated, at present, Lizhu in the study of micro-ball varieties are fully promoted, is expected to win a number of domestic first imitation.
    Table 4: Biopharmaceiters declared by Lizhu 2017 to date Source: MED2.0 China Drug Review Database Lizhu in the field of biopharmaceiters focused on the promotion of varieties including injectable recombinant human velvet, the current Product listing application is being reviewed and approved, is expected to win the first domestic in 2021; Drug, currently Phase III. Clinical has been completed, the fastest progress, injection with recombinant tumor enzyme-specific interferon α-2b Fc fusion protein is a long-acting targeted cytokine prescell drug, the drug enters the human body after the human body The main pre-existing drug forms exist in the exosome circulatory system and normal tissue, when the prebiotic drug enters the tumor tissue, exposes the active ingredients of the drug and plays a specific anti-tumor effect at a specific tumor site, the new drug is a global innovation drug, which has attracted much attention from the industry.
    a sword, 17 million Hetty "special effects medicine" domestic first imitation table 5: 2020 Lizhu approved product situation Source: MED 2.0 China Drug Review Database Lizhu mentioned in the announcement, injection of danqulin sodium is the company after 10 years of independent research and development of generic drugs, used to prevent and treat malignant high fever, as of the announcement date, the project invested about 17.2234 million yuan in research and development costs.
    In China, the incidence of malignant high fever is extremely low, but the mortality rate is very high, up to 70% to 80%;
    lizhu was approved for the first imitation, to solve the domestic drug-free state.
    benzene sulfonate chloride capsules for the national health insurance Class A varieties, a total of 2 domestic enterprises have been approved, Lizhu is the first over-evaluation enterprises, the company in the project has invested a cumulative research and development costs of about 10.6931 million yuan.
    2019 in China's public medical institutions terminal sales of more than 200 million yuan, in the first half of 2020 Lizhu's market share of more than 51%, won the market leader position.
    Table 6: Lizhu is currently under review for the listing of chemical drugs (statistics including joint declaration) Source: Minet MED2.0 China Drug Review Database injection of tyga cyclin in China's public medical institutions terminal is more than 2 billion large varieties of whole-body anti-bacterial drugs, in addition to Pfizer's original research products approved for import, there are 8 domestic enterprises Access to production approval, no enterprise evaluation, but the rise of domestic generic drugs is strong, in the first half of 2020 in China's public medical institutions terminal Jiangsu Howson Pharmaceutical Group with 35.75 percent market share leader, Pfizer slipped to 27.24 percent, Lizhu's acceptance number has now entered the approval process, after approval can seize how many markets? We'll see.
    's innovative biopharmaceus and high-end complex preparations are long-term layout, in addition to a number of exclusive products have been listed to lead the performance soaring, the diagnostic field of independent research and development products have also entered the harvest period: 2020 approved for the listing of the new coronavirus (2019-nCoV) IgM/ IgG anti-medical test kit (collage gold method) in domestic and foreign markets have achieved new sales, providing important support for performance growth.
    in addition, Lizhu's API business is also expected to provide flexible value-added performance, on the one hand, the product from bulk API to high-end specialty API, on the other hand, the market also to Europe and the United States and other standardized market transformation, and continue to increase marketing efforts, is expected to continue to provide better profit contribution in the next few years.
    : Company Announcement, Minet Database Note: Review data statistics as of February 2, 2021, if there are errors, please point out.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.